Eden Research Balance Sheet Health

Financial Health criteria checks 6/6

Eden Research has a total shareholder equity of £12.7M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £15.0M and £2.3M respectively.

Key information

Debt to equity ratio

UK£0

Debt

Interest coverage ratio	n/a
Cash	UK£4.95m
Equity	UK£12.71m
Total liabilities	UK£2.32m
Total assets	UK£15.03m

Recent financial health updates

Recent updates

We Think Eden Research (LON:EDEN) Can Afford To Drive Business Growth

Aug 25

We Think Eden Research (LON:EDEN) Needs To Drive Business Growth Carefully

Jul 09

We're Keeping An Eye On Eden Research's (LON:EDEN) Cash Burn Rate

Mar 05

We Think Eden Research (LON:EDEN) Needs To Drive Business Growth Carefully

Nov 06

Companies Like Eden Research (LON:EDEN) Are In A Position To Invest In Growth

Jul 07

We're Hopeful That Eden Research (LON:EDEN) Will Use Its Cash Wisely

Feb 18

A Look At Eden Research's (LON:EDEN) Share Price Returns

Dec 25

We're Hopeful That Eden Research (LON:EDEN) Will Use Its Cash Wisely

Nov 19

Financial Position Analysis

Short Term Liabilities: EDEN's short term assets (£8.7M) exceed its short term liabilities (£2.3M).

Long Term Liabilities: EDEN's short term assets (£8.7M) exceed its long term liabilities (£19.6K).

Debt to Equity History and Analysis

Debt Level: EDEN is debt free.

Reducing Debt: EDEN had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EDEN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EDEN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 14.8% each year

Eden Research Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Eden Research Delists from the OTCQB Exchange in the US

We Think Eden Research (LON:EDEN) Can Afford To Drive Business Growth

We Think Eden Research (LON:EDEN) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Eden Research's (LON:EDEN) Cash Burn Rate

We Think Eden Research (LON:EDEN) Needs To Drive Business Growth Carefully

Companies Like Eden Research (LON:EDEN) Are In A Position To Invest In Growth

Recent updates

New major risk - Financial position

Eden Research Delists from the OTCQB Exchange in the US

First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.015 loss in 1H 2023)

Eden Research plc to Report First Half, 2024 Results on Sep 23, 2024

Eden Research plc Announces Temporary Approval for Cedroz in Greece

Eden Research plc Announces Executive Changes

Eden Research plc Announces Biofungicide Regulatory Authorisation in Germany

Eden Research plc Announces Appointment of Daniel Mulas García as Global Product and Marketing Lead

Eden Research plc Announces Biofungicide Label Extension in Spain

Eden Research plc Appoints Humair Tariq as New Global Commercial Lead

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Eden Research plc to Report Fiscal Year 2023 Results on May 07, 2024

Eden Research plc Announces Appointment of Derek Mcallan as Non-Executive Director and as Chairman of the Audit Committee Following the Company's 2024 AGM

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Financial data availability

Insufficient new directors

Eden Research plc Announces Richard Horsman to Stepped Down as Non-Executive Director

Eden Research plc Provides Revenue Guidance for the Full Year of 2023

First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.003 loss in 1H 2022)

Eden Research plc to Report First Half, 2023 Results on Sep 29, 2023

New major risk - Revenue and earnings growth

We Think Eden Research (LON:EDEN) Can Afford To Drive Business Growth

New minor risk - Shareholder dilution

Eden Research plc Announces Regulatory Application for Authorised Use of Ecovelex™ in the United Kingdom

New major risk - Share price stability

Eden Research plc, Annual General Meeting, Jun 29, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Eden Research plc to Report Fiscal Year 2022 Results on May 05, 2023

Eden Research plc Announces First Mevalone Authorisation for Domestic Use

Eden Research plc Provides Revenue Guidance for the Full Year of 2022

Less than half of directors are independent

First half 2022 earnings released: UK£0.003 loss per share (vs UK£0.004 loss in 1H 2021)

Eden Research plc Grants US EPA Regulatory Approval

Eden Research plc Appoints Richard Horsman as Non-Executive Director, with effect from 1 September 2022

We Think Eden Research (LON:EDEN) Needs To Drive Business Growth Carefully

Eden Research plc, Annual General Meeting, Jun 29, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Eden Research plc Announces Progress Towards EPA Approval and Further Authorisation in Italy

Insufficient new directors

We're Keeping An Eye On Eden Research's (LON:EDEN) Cash Burn Rate

We Think Eden Research (LON:EDEN) Needs To Drive Business Growth Carefully

First half 2021 earnings released: UK£0.004 loss per share (vs UK£0.004 loss in 1H 2020)

Eden Research plc Announces New Label Extension for Biofungicide in Portugal

Companies Like Eden Research (LON:EDEN) Are In A Position To Invest In Growth

Full year 2020 earnings released: UK£0.007 loss per share (vs UK£0.005 loss in FY 2019)

New 90-day high: UK£0.20

We're Hopeful That Eden Research (LON:EDEN) Will Use Its Cash Wisely

A Look At Eden Research's (LON:EDEN) Share Price Returns

We're Hopeful That Eden Research (LON:EDEN) Will Use Its Cash Wisely

First half earnings released

Eden Research plc Announces New Authorisations for Cedroz™ and Mevalone®

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Cash Runway Analysis

Discover healthy companies